Drug Topics
MAY 13, 2025
Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.
STAT
MAY 13, 2025
Leading trade organizations representing the makers of cell and gene therapies are calling for a 10-year international moratorium on the use of CRISPR and other DNA-editing tools to create genetically modified children, according to a draft of the declaration provided to STAT. The move — coming more than seven years after Chinese researcher He Jiankui announced the birth of the world’s first CRISPR babies — is intended to send a clear signal to the global scientific co
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MAY 13, 2025
In the second part of our interview with Miranda Rochol, she discusses challenges regarding digital prescription solutions and the financial burdens these solutions are designed for pharmacists to overcome.
STAT
MAY 13, 2025
For a recent therapy session, Andria Donaghy’s insurance plan paid her psychiatric nurse practitioner only $11 on a $125 service. “To even put that on paper is insulting,” she said. “These people give their lives [to help others] and that’s what you pay them?
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
MAY 13, 2025
Administration during peak vaccine effectiveness provides maximal protective benefit
Fierce Healthcare
MAY 13, 2025
This is the beginning of a new era for HHS and American health more broadly, HHS Secretary Robert F. Kennedy Jr. wrote in a Tuesday notice. In this new era, patient choice and individual freedom will predominate over burdensome federal regulations.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmafile
MAY 13, 2025
Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to current antipsychotics in patients with treatment-resistant schizophrenia (TRS). This is a significant milestone Newrons endeavour to rollout the therapy as a conventional treatment for these patients. The ENIGMA-TRS phase 3 development programme consists of two […] The post Newrons programme for treatment-resistant schizophrenia therapy approved a
Pharmacy Times
MAY 13, 2025
FDA and CDC halt Ixchiq chikungunya vaccine for adults 60 years and older due to severe adverse events, including fatalities, urging caution in vaccination practices.
Fierce Healthcare
MAY 13, 2025
The CMS Innovation Center rolled out its blueprint to reverse chronic disease and test more effective payment models Tuesday.
Pharmacy Times
MAY 13, 2025
Despite being an effective treatment option, intravenous immunoglobulin (IVIG) can cause transient adverse events in pediatrics with primary immunodeficiency, including headache and fever.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmaceutical Technology
MAY 13, 2025
AI and machine learning can transform fragmented and unstructured healthcare data. But how do you refine it into useful, research-ready data?
Pharmacy Times
MAY 13, 2025
Artificial intelligence (AI) can transform rare disease research by leveraging patient data, enhancing evidence generation, and improving communication between patients and health care professionals.
pharmaphorum
MAY 13, 2025
Bayer's CEO says newer product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025
Pharmaceutical Technology
MAY 13, 2025
The FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The Checkup by Singlecare
MAY 13, 2025
If you have certain lung conditions, you may be prescribed a Dulera inhaler. Dulera is a prescription medication that combines two active ingredients: formoterol fumarate dihydrate and mometasone. It is FDA approved to help manage symptoms of asthma and improve lung function in adults and pediatric patients five years of age and older. Dulera is also prescribed off-label to help with breathing problems in adults with chronic obstructive pulmonary disorder (COPD).
PharmExec
MAY 13, 2025
Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.
Pharmaceutical Technology
MAY 13, 2025
Abeonas deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.
PharmExec
MAY 13, 2025
Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how repurposing GLP-1s and psychedelics for addiction treatment introduces unexpected patent challenges, liability concerns, and complex state-by-state regulatory hurdles.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
MAY 13, 2025
Mobile healthcare, web-based tech, and wearables are all contributing to a clinical trials landscape that puts the patient first.
PharmExec
MAY 13, 2025
The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
Pharmaceutical Technology
MAY 13, 2025
The UK MHRA has approved AstraZeneca's Trixeo Aerosphere inhaler to treat adults with chronic obstructive pulmonary disease (COPD).
PharmExec
MAY 13, 2025
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
MAY 13, 2025
GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate the market.
Pharmaceutical Commerce
MAY 13, 2025
In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs senior director of DSCSA/serialization compliance services, discusses the obstacles in documenting and proving DSCSA compliance.
PharmD Live
MAY 13, 2025
Meeting the Moment in Primary Care As the U.S. healthcare system transitions toward value-based care, primary care clinics face increasing pressure to deliver holistic, coordinated, and cost-effective services, especially for aging Medicare beneficiaries with multiple chronic conditions. The “Silver Tsunami” continues to expand the Medicare population, rendering traditional fee-for-service (FFS) models obsolete.
European Pharmaceutical Review
MAY 13, 2025
New research has proposed a novel approach for treating early-stage breast cancer with inherited BRCA1 and BRCA2 gene mutations. One hundred percent of patients survived three-years post-surgery, indicating the most effective treatment to date for this indication. Current standard treatment involves chemotherapy and immunotherapy to shrink the tumour, before surgical removal.
Pharmaceutical Commerce
MAY 13, 2025
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
Drug Topics
MAY 13, 2025
Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.
PharmaVoice
MAY 13, 2025
Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.
Drug Topics
MAY 13, 2025
Patients with psychosis, depression, and anxiety exhibit higher rates of vaccine hesitancy.
PharmaVoice
MAY 13, 2025
Who’s in, who’s out and which key positions are still left to be filled in an agency upended.
Drug Topics
MAY 13, 2025
Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.
STAT
MAY 13, 2025
UnitedHealth Group said Tuesday that CEO Andrew Witty had stepped down, citing personal reasons, and that it had named its board chair and former chief executive Stephen Hemsley as the company’s new leader. Hemsley, who was UnitedHealth’s CEO from 2006 to 2017, will remain the company’s chair. UnitedHealth also announced it was suspending its 2025 outlook, saying “care activity continued to accelerate” and that “the medical costs of many Medicare A
Expert insights. Personalized for you.
247 
Let's personalize your content